ES2065034T3 - Sistema compuesto molecular para la terapia contraescalativa de las enfermedades infecciosas viricas. - Google Patents

Sistema compuesto molecular para la terapia contraescalativa de las enfermedades infecciosas viricas.

Info

Publication number
ES2065034T3
ES2065034T3 ES91909678T ES91909678T ES2065034T3 ES 2065034 T3 ES2065034 T3 ES 2065034T3 ES 91909678 T ES91909678 T ES 91909678T ES 91909678 T ES91909678 T ES 91909678T ES 2065034 T3 ES2065034 T3 ES 2065034T3
Authority
ES
Spain
Prior art keywords
lpl
plp
units
infectious diseases
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909678T
Other languages
English (en)
Inventor
Chantal Mach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2065034T3 publication Critical patent/ES2065034T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

LA INVENCION CONCIERNE A UN SISTEMA COMPUESTO MOLECULAR PARA LA QUIMIOTERAPIA RESTITUTIVA DE ENFERMEDADES INFECCIOSAS VIRALES, OBTENIBLE MEDIANTE (I) LA PRODUCCION DE UNIDADES DE LIGNINA RICAS EN POLISACARIDOS (PLP) MEDIANTE: EXTRACCION EN MEDIOS ACUOSOS EN UN MEDIO DEBILMENTE ACIDO HASTA ALCALINO DE MADERA O MATERIALES TIPO MADERA TAMBIEN DE (O) CULTIVOS CELULARES VEGETALES (A); SEPARACION DE LOS COMPONENTES SOLIDOS INSOLUBLES; (II) PRODUCCION DE UNIDADES LIGNOIDES POBRES EN POLISACARIDOS DE BAJO PESO MOLECULAR (LPL) MEDIANTE: EXTRACCION ACUOSO-ALCALINA (PH 7-14) DE PRODUCTOS DE CARBONIZACION DE LA MADERA O MATERIALES TIPO MADERA BIOCONVERTIDOS (B); SEPARACION DE LOS COMPONENTES SOLIDOS INSOLUBLES EN ALCALIS ; (III) PRODUCCION DE UN POLIMERIZADO MIXTO SOLUBLE EN AGUA LD (PLP=LPL) MEDIANTE: TRANSFORMACION DEL PRODUCTO DE LA ETAPA I), LAS UNIDADES DE LIGNINA RICAS EN POLISACARIDOS (PLP) CON LOS PRODUCTOS DE LA ETAPA II), LAS UNIDADES LIGNOIDES POBRES EN POLISACARIDOS (LPL) BAJO CONDICIONES ACUOSO-ALCALINAS (PH 9-12); AISLAMIENTO DE LAS FRACCIONES LD DE ESTE POLIMERIZADO MIXTO HD-PLP=LPL MEDIANTE ULTRAFILTRACION A UNOS VALORES DE CORTE NOMINALES DE APROX. 15 A 40 KD, EN DONDE SE DESECHA EL RETENTADO; TRATAMIENTO DE LA SOLUCION CON UN INTERCAMBIADOR DE CATIONES H+ A UN PH DE 3 HASTA 7,0, ASI COMO TRATAMIENTO POSTERIOR DEL SISTEMA ACIDO LD(LPL-PLP), QUE SE PUEDE APLICAR ESPECIALMENTE COMO SISTEMA DE SUSTANCIAS ACTIVAS INHIBIDORAS DE VIRUS APLICABLE PARENTERAL O LOCALMENTE PARA COMBATIR LAS ENFERMEDADES INFECCIOSAS VIRALES, EN DONDE LOS VIRUS PUEDEN SER RETROVIRUS, ESPECIALMENTE DEL TIPO HIV, TAMBIEN VIRUS DEL SIDA.
ES91909678T 1990-05-27 1991-05-27 Sistema compuesto molecular para la terapia contraescalativa de las enfermedades infecciosas viricas. Expired - Lifetime ES2065034T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4017091A DE4017091A1 (de) 1990-05-27 1990-05-27 Molekuelverbundsystem zur kontra-eskalativen therapie viraler infektionskrankheiten

Publications (1)

Publication Number Publication Date
ES2065034T3 true ES2065034T3 (es) 1995-02-01

Family

ID=6407309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909678T Expired - Lifetime ES2065034T3 (es) 1990-05-27 1991-05-27 Sistema compuesto molecular para la terapia contraescalativa de las enfermedades infecciosas viricas.

Country Status (17)

Country Link
US (2) US5554596A (es)
EP (1) EP0535001B1 (es)
JP (1) JP2905289B2 (es)
AT (1) ATE110275T1 (es)
AU (1) AU663684B2 (es)
BG (1) BG61154B1 (es)
CA (1) CA2084093C (es)
DE (2) DE4017091A1 (es)
DK (1) DK0535001T3 (es)
ES (1) ES2065034T3 (es)
FI (1) FI925363A (es)
HU (2) HUT68910A (es)
NO (1) NO306049B1 (es)
PL (1) PL168266B1 (es)
RO (1) RO113430B1 (es)
RU (1) RU2104016C1 (es)
WO (1) WO1991018616A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348503B1 (en) 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US6355684B1 (en) 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6350784B1 (en) 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
DE4236346A1 (de) * 1992-10-28 1994-05-05 Chantal Dr Mach Wirkstoffgruppe, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE4316347C1 (de) * 1993-02-26 1994-08-18 Ina Dr Levi Verfahren zur Herstellung einer pharmazeutischen Zubereitung und Verwendung derselben zur Behandlung bestimmter Erkrankungen
DE4415087A1 (de) * 1994-04-29 1995-11-09 Zschiegner Hans Joachim Dr Mittel als Wirkstoffe bzw. Wirkstoffgemische zur Anwendung in der Balneotherapie, Gesundheitspflege und Kosmetik und Verfahren zur Herstellung pharmazeutischer Erzeugnisse sowie Verfahren zu ihrer Anwendung
DE4417254A1 (de) * 1994-05-17 1995-11-23 Zschiegner Hans Joachim Dr Mittel als Wirkstoffe bzw. Wirkstoffgemische für Tierarzneimittel, Tiergesundheitspflegemittel, Medizinalfuttermittel, Ergotropika und zur Anwendung in der Veterinärhygiene sowie Verfahren zur Herstellung der Mittel und pharmazeutischer Erzeugnisse und Methoden ihrer Anwendung
FR2731162B1 (fr) * 1995-03-01 1997-04-11 Oreal Procede d'extraction d'au moins un actif a partir de cellules vegetales indifferenciees
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
FR2757046B1 (fr) * 1996-12-16 1999-03-05 Dior Christian Parfums Utilisation d'un extrait de resine d'okoume, dans les domaines cosmetique et pharmaceutique, notamment dermatologiques
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
RU2141335C1 (ru) * 1998-12-30 1999-11-20 Общество с ограниченной ответственностью "Лигфарм" Противоопухолевое средство "олипифат" и способ его получения
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
RU2172176C1 (ru) * 2000-06-19 2001-08-20 Общество с ограниченной ответственностью "Нобель" Способ получения противовирусного средства
US6866875B2 (en) * 2001-09-26 2005-03-15 Tampa Bay Research Institute Pine cone extracts and uses thereof
US7838046B2 (en) * 2001-09-26 2010-11-23 Tampa Bay Research Institute Plant extracts and uses thereof
US6703053B2 (en) * 2001-10-24 2004-03-09 Tampa Bay Research Institute Anti-HSV agent for inhibiting replication of HSV-1 and HSV-2 and method of producing a substance having anti-HSV activity
EP2422805A1 (en) * 2003-12-24 2012-02-29 Ramot at Tel-Aviv University Ltd. Antiviral preparations obtained from a natural cinnamon extract
RU2401117C1 (ru) * 2009-04-06 2010-10-10 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Средство для профилактики гриппа и острых респираторных заболеваний
JP2010273569A (ja) * 2009-05-26 2010-12-09 Wasaburo Sato メタボリックシンドローム改善作用を有する飲料及びサプリメント
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185097A (en) * 1978-01-09 1980-01-22 A. H. Robins Company, Inc. Method of combating Herpes simplex viruses with lignosulfonates
JPS54154507A (en) * 1978-05-22 1979-12-05 Eisai Co Ltd Inactivating agents for hbs anitgen
DE3068159D1 (en) * 1980-03-12 1984-07-19 Mach Walter Dr Biochemically active ingredient, process for its production and a pharmaceutical preparation that contains this ingredient
JPS5939411B2 (ja) * 1980-12-24 1984-09-22 野田食菌工業株式会社 抗動物ウイルス剤
JPS57130919A (en) * 1981-02-06 1982-08-13 Eisai Co Ltd Lignin-containing virucide
DE3206911A1 (de) * 1982-02-26 1983-09-15 Lohmann Tierernährung GmbH, 2190 Cuxhaven Biochemischer wirkstoff, dessen herstellung und diesen wirkstoff enthaltendes mittel
DE3707909A1 (de) * 1987-03-12 1988-09-22 Ruetgerswerke Ag Niedermolekulare alkalihuminate, verfahren zu ihrer herstellung und verwendung
US4985249A (en) * 1987-06-26 1991-01-15 Hiroshi Sakagami Anti-HIV agents
US4988799A (en) * 1987-08-11 1991-01-29 Daishowa Chemicals Inc. Lignosulfonate based pharmacologic agent with anti-coagulant and anti-thrombotic activity
JP2602715B2 (ja) * 1988-04-12 1997-04-23 日本製紙 株式会社 抗ウィルス性医薬用組成物
US4935239A (en) * 1988-04-12 1990-06-19 Sanyo-Kokusaku Pulp Co., Ltd. Composition for antiviral medicines
JPH02262524A (ja) * 1989-03-31 1990-10-25 Shozo Toda エイズウイルス増殖抑制剤
CA1335259C (en) * 1989-03-31 1995-04-18 Makoto Machida Composition of spent liquor from pulping process for antiviral medicine
JPH02286623A (ja) * 1989-04-27 1990-11-26 Noda Shiyokukin Kogyo Kk 抗ウイルス物質及びその製法
JPH03120223A (ja) * 1989-10-04 1991-05-22 Sanyo Kokusaku Pulp Co Ltd 抗ウイルス性医薬用組成物
JP2923660B2 (ja) * 1990-01-06 1999-07-26 宏 坂上 ウイルス感染防止剤
JP2938916B2 (ja) * 1990-01-10 1999-08-25 日本ケミカルリサーチ株式会社 ヘルペスウィルスの増殖阻害および潜伏感染後の再発阻止剤

Also Published As

Publication number Publication date
WO1991018616A1 (de) 1991-12-12
NO924575L (no) 1993-01-12
BG97122A (bg) 1993-12-24
US5554596A (en) 1996-09-10
JP2905289B2 (ja) 1999-06-14
EP0535001B1 (de) 1994-08-24
HU9203747D0 (en) 1993-03-29
HU211541A9 (en) 1995-12-28
FI925363A0 (fi) 1992-11-25
RU2104016C1 (ru) 1998-02-10
EP0535001A1 (de) 1993-04-07
AU7892891A (en) 1991-12-31
AU663684B2 (en) 1995-10-19
FI925363A (fi) 1992-11-25
NO306049B1 (no) 1999-09-13
DE4017091A1 (de) 1991-11-28
NO924575D0 (no) 1992-11-26
DE59102660D1 (de) 1994-09-29
PL168266B1 (pl) 1996-01-31
BG61154B1 (bg) 1997-01-31
ATE110275T1 (de) 1994-09-15
US5698524A (en) 1997-12-16
CA2084093C (en) 2002-10-22
RO113430B1 (ro) 1998-07-30
HUT68910A (en) 1995-08-28
CA2084093A1 (en) 1991-11-28
DK0535001T3 (da) 1995-02-20
JPH05507270A (ja) 1993-10-21

Similar Documents

Publication Publication Date Title
ES2065034T3 (es) Sistema compuesto molecular para la terapia contraescalativa de las enfermedades infecciosas viricas.
RU92016546A (ru) Группа активных веществ для восстановительной химиотерапии
SI2833905T1 (en) Combination therapy with hyaluronidase and tumane-directed taxane
ES2087335T3 (es) Membranas hidrofilas sinteticas y procedimiento para su produccion.
EA202190567A1 (ru) Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
US20110027240A1 (en) Secretable hiv entry inhibitory peptides for therapy of hiv infection
ES2099588T3 (es) Proceso para la preparacion de acido n-fosfonometilimino-diacetico.
AR029810A1 (es) Metodos y composiciones para la inhibicion de los acontecimientos asociados con la fusion de membrana, incluyendo la transmision de rsv
Yip et al. Antiviral activity of a derivative of the photosensitive compound hypericin
US5223258A (en) Antiviral disinfecting composition and method of inactivating the aids virus in vitro
Arsène Lessons for SARS-CoV-2 study (COVID-19 disease) from its exosome relatives
Hayami Seroactive pattern and isolation of HIV in Ghana
Humaira et al. Antiviral, embryo toxic and cytotoxic activities of Astragalus membranaceus root extracts
MX164795B (es) Inactivacion mediante fenoles del virus de la inmunodeficiencia humana(hiv),en soluciones con contenido de proteinas
Schelling et al. Protection from a dormant time bomb: The development of effective vaccines against herpes zoster
Liu et al. Bone transport technique versus induced membrane technique for treatment of infected bone nonunion
ES2061611T3 (es) Quelatos de esteres acetoaceticos-titanio condensados y procedimiento para su preparacion.
CN1058609C (zh) 化合物摩鲁新(morusin)的医药用途
Oyun et al. COMPARISON STUDY OF MOUTH SORES AND IMMUNOLOGICAL CHANGES AMONG PEOPLE WITH HIV INFECTION
KR20090115393A (ko) 인삼의 잎과 줄기추출물을 이용한 양돈용 사료첨가제
CN105454271A (zh) 用于防除甘蔗田杂草的除草组合物
ES2118052B1 (es) Perfeccionamientos introducidos a la patente n- 9601181 por procedimiento para la preparacion de un extracto como base para la obtencion de medicamentos para el tratamiento de dolencia humanas de origen virico.
Wang et al. Progess of the broad spectrum anti-viral effect of ginsenosides
Wang et al. Genetic analysis of human immunodeficiency virus type 1 strains from AIDS patients in Shenzhen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 535001

Country of ref document: ES